Format

Send to

Choose Destination
J Immunol Methods. 2011 Jan 5;363(2):120-34. doi: 10.1016/j.jim.2010.09.036. Epub 2010 Oct 11.

Recommendations for the validation of flow cytometric testing during drug development: II assays.

Author information

1
Pharmacokinetics, Dynamics and Metabolism, Pfizer (formerly Wyeth), 35 Cambridge Park Drive, Cambridge, MA 02140, USA. Denise.O'Hara@pfizer.com

Abstract

Flow cytometry-based assays serve as valuable tools for various aspects of the drug development process ranging from target discovery and characterization to evaluation of responses in a clinical setting. The integrity of the samples and the appropriate selection and characterization of the reagents used in these assays are in themselves challenging. These concerns taken together with the flow-based technology makes the validation of flow cytometry assays a challenging effort. Therefore, apart from summarizing the role of flow cytometry technology in various stages of drug development, this manuscript focuses on recommendations for the validation of methods applying flow cytometry. Information is also provided on the relevant validation parameters for different types of flow cytometry assays to guide the users of this platform. Together, the recommendations and the information on regulatory guidelines provided in this manuscript represent the consensus of all the authors and can assist the flow cytometry user in implementing the appropriate method validation strategies.

PMID:
20946898
DOI:
10.1016/j.jim.2010.09.036
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center